Alveolar hemorrhage as a complication of treatment with abciximab

被引:37
作者
Kalra, S
Bell, MR
Rihal, CS
机构
[1] Mayo Clin & Mayo Fdn, Div Pulm & Crit Care Med, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, Rochester, MN 55905 USA
[3] Mayo Clin & Mayo Fdn, Dept Internal Med, Rochester, MN 55905 USA
关键词
abciximab; alveolar hemorrhage; complications; ReoPro;
D O I
10.1378/chest.120.1.126
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Study objective: The use of abciximab, a chimeric monoclonal antibody Fab fragment specific for platelet glycoprotein IIb/IIIa receptors, is associated with improved outcome after angioplasty and stent placement. Major complications include bleeding, but pulmonary hemorrhage has been reported rarely. This study was done to identify patients with pulmonary hemorrhage following abciximab infusion and to define, if possible, any specific risk factors, Design: Retrospective review of institutional coronary angiography and bronchoscopy databases to identify patients who received abciximab and developed pulmonary hemorrhage. Setting: Tertiary-care teaching hospital. Patients: All patients who underwent coronary angiography and received abciximab between June 1995 and March 2000, Intervention: None. Measurements and results: Seven of 2,553 patients (0.27%) had documented se, cre pulmonary hemorrhage associated with chest radiographic abnormalities, impaired oxygenation, and the need for blood product transfusions. The initial symptom was hemoptysis in four of the seven patients. There were two early deaths and one late death. No cases of pulmonary hemorrhage were identified in 5,412 patients who underwent coronary procedures without abciximab infusion. No other risk factors predicting hemorrhage were identified. Conclusions: Severe pulmonary hemorrhage is a complication of abciximab use. Although hemoptysis is an important alerting symptom, it may not he present initially and the diagnosis may be missed or considered late, with the potential for inappropriate treatment until the diagnosis is established. Lesser degrees of bleeding are potentially easily missed, and this report should alert physicians to this complication so that it can be considered early in the evaluation of patients presenting with pulmonary events after abciximab use.
引用
收藏
页码:126 / 131
页数:6
相关论文
共 10 条
  • [1] Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization
    Berkowitz, SD
    Sane, DC
    Sigmon, KN
    Shavender, JH
    Harrington, RA
    Tcheng, JE
    Topol, EJ
    Califf, RM
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (02) : 311 - 319
  • [2] PULMONARY HEMORRHAGE AFTER INTRACORONARY STENT PLACEMENT
    BROWN, DL
    MACISAAC, AI
    TOPOL, EJ
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1994, 24 (01) : 91 - 94
  • [3] USE OF A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY
    CALIFF, RM
    SHADOFF, N
    VALETT, N
    BATES, E
    GALEANA, A
    KNOPF, W
    SHAFTEL, J
    BENDER, MJ
    AVERSANO, T
    RAQUENO, J
    GURBEL, P
    COWFER, J
    COHEN, M
    CROSS, P
    BITTL, J
    EDDINGS, K
    TAYLOR, M
    DEROSA, K
    HATTEL, L
    COOPER, L
    ESHELMAN, B
    FINTEL, D
    NIEMYSKI, P
    KLEIN, L
    KENNEDY, H
    THORNTON, T
    KEREIAKES, D
    MARTIN, L
    ANDERSON, L
    HIGBY, N
    ELLIS, S
    BREZINA, K
    GEORGE, B
    CHAPEKIS, A
    SMITH, D
    ANWAR, A
    GERBER, TL
    PRITCHARD, GL
    MYLER, R
    SHAW, R
    MURPHY, M
    WARD, K
    MADIGAN, NP
    BLANKENSHIP, J
    HALBERT, M
    FLANAGAN, C
    TANNENBAUM, M
    POLICH, M
    STEVENSON, C
    TCHENG, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (14) : 956 - 961
  • [4] Khanlou H, 1998, NEW ENGL J MED, V339, P1861
  • [5] Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization
    Lincoff, AM
    Tcheng, JE
    Califf, RM
    Bass, T
    Popma, JJ
    Teirstein, PS
    Kleiman, NS
    Hattel, LJ
    Anderson, HV
    Ferguson, JJ
    Cabot, CF
    Anderson, KM
    Berdan, LG
    Musco, MH
    Weisman, HF
    Topol, EJ
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1997, 79 (03) : 286 - 291
  • [6] Simoons ML, 1997, LANCET, V349, P1429
  • [7] Massive pulmonary hemorrhage in a patient treated with a platelet glycoprotein IIb/IIIa inhibitor
    Sitges, M
    Villa, FP
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 1997, 62 (03) : 269 - 271
  • [8] Incidence of bleeding complications associated with Abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty
    Sundlof, DW
    Rerkpattanapitat, P
    Wongpraparut, N
    Pathi, P
    Kotler, MN
    Jacobs, LE
    Ledley, GS
    Yazdanfar, S
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1999, 83 (11) : 1569 - +
  • [9] Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
    Topol, EJ
    Lincoff, AM
    Califf, RM
    Tcheng, JE
    Kleiman, NS
    Adelman, AG
    Burton, JR
    Talley, JD
    Ivanhoe, RJ
    Ducas, C
    Cheung, PK
    Schick, U
    Badard, D
    Kramer, J
    Leary, J
    Snyder, H
    Wilson, R
    Dearen, M
    Caramori, P
    Webber, S
    Taylor, J
    Ferrando, T
    Cohen, E
    Balleza, L
    Rouse, C
    Hogg, N
    Kelly, T
    Alston, S
    Webb, J
    Buller, E
    Ricci, DR
    Mockman, S
    Tanguay, JF
    Poitras, AM
    Timis, G
    Davey, D
    Coleman, P
    Herrold-Runge, P
    O'Neill, BJ
    Foshey, K
    Fitzgerald, N
    Almond, D
    Kostuk, W
    White, J
    Oskalns, R
    Gottlieb, R
    Koren, P
    Palazzo, D
    Azrin, M
    Barry, MB
    [J]. LANCET, 1998, 352 (9122) : 87 - 92
  • [10] Topol EJ, 1997, NEW ENGL J MED, V336, P1689